Comment from U.S. Chamber of Commerce

Summary: The U.S. Chamber of Commerce supports the FDA's proposed pilot program to use AI in early-phase clinical trials, praising its voluntary and structured approach. They recommend aligning the pilot with principles of efficiency, neutrality, proportionality, collegiality, and flexibility while ensuring robust protection of intellectual property and human accountability.